Proteolysis targeting chimera (Protein Degrader) technology represents a breakthrough development in the field of drug discovery, utilizing the ubiquitin proteasome system to specifically degrade disease-related proteins. Protein Degraders are characterized by theirRead More…
N 6-methyladenosine (m6A) methylation is the most abundant type of RNA modification, primarily catalyzed by the METTL3-METTL14 methyltransferase complex (MTC). This complex includes the core catalytic proteins METTL3 and METTL14, as wellRead More…
When targeting harmful proteins that cause or spread disease, drugs usually block the protein’s active site, making it unable to function and causing severe damage. New strategies targeting these proteins may sendRead More…
Recently, the Li Zigang and Yin Feng research group of Shenzhen Graduate School of Peking University published a research paper entitled “Targeted biomolecule regulation platform: a Split-and-Mix Protein Degrader approach” in JournalRead More…
Main steps of Protein Degrader to achieve intracellular protein degradation To achieve intracellular protein degradation requires multiple steps, such as cellular uptake, effective recruitment of E3 ligase, ubiquitination of target proteins, andRead More…
In 2004, the Nobel Prize in Chemistry was awarded to Israeli scientists Aaron Sichanova, Afram Hershko and American scientist Irwin Ross for their discovery of ubiquitin-regulated protein degradation. Protein degradation is ratedRead More…
In recent years, targeted protein degradation chimera (Protein Degrader) as a novel way to induce protein degradation has become a new drug discovery strategy. Compared with traditional protein inhibitor drugs, it hasRead More…